Dear Investors,

I have received several inquiries about our October 8th press release. It marks an exciting and historic milestone for Ocumetics. The patients selected for our first clinical group entered the study with very poor functional vision due to cataracts and were struggling to see clearly at distance.

One month following cataract surgery and implantation of the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”), their vision has improved dramatically to 20/40 or better, an extraordinary outcome at this early stage.

It’s important to note that patients must continue to heal and adapt after cataract surgery, and best vision typically develops over three to six months. The fact that our participants are seeing this level of improvement so soon after surgery is remarkable in its speed, while still aligning with the expected course of visual recovery.

These outcomes reinforce the safety, performance, and promise of the Ocumetics Lens. They demonstrate that our technology is behaving exactly as designed, offering patients the potential for clear, natural vision across all distances.

We invite you to read the October 8th press release for details, but in summary:

  • The safety profile remains excellent.
  • Surgical handling and implantation have been both smooth and reproducible.
  • Patients with previously poor vision are now experiencing clear, functional sight and improvement is expected to continue.

This is tremendous news for Ocumetics, for our partners, and most importantly for patients worldwide who dream of life without glasses or contacts. We are building momentum, and I am more confident than ever that Ocumetics is redefining the future of vision.

Warm regards,

Dean Burns

President & CEO

Ocumetics Technology Corp.

  • Ocumetics Announces Initiation of Patient Recruitment for Upcoming Group Two Human Clinical Surgeries

    Key Highlights Group Two clinical study underway – Patient recruitment has begun in Mexico City, with surgeries targeted for Fall 2026. Moving beyond safety – The Group Two study will evaluate the Ocumetics Lens for safety plus near-and distance-vision performance. Next-generation technology – Patients will receive the latest-generation Ocumetics Lens implanted with an enhanced delivery system. 12-month data milestone approaching – Group One patients are

  • Ocumetics Announces Completion of Third and Final Tranche of Unit Private Placement

    Calgary, Alberta – TheNewswire – August 24, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the third and final tranche of the private placement previously announced by the Corporation on July 7, July 29, July 30, 2026 and July 31, 2026 (the “Offering”).   The Corporation

  • Ocumetics Accelerates Toward Group Two First-In-Human Study with Manufacturing Launch of Optimized Accommodating Lens

    Key Highlights Precision molds received for manufacturing of new optimized accommodating intraocular lenses Production and testing of next-generation lenses now underway New lens design incorporates insights from Group One First-in-Human study Group Two preclinical surgeries targeted for early Q3 2026 FDA Investigational Device Exemption (IDE) preparation advancing Calgary, Canada – TheNewswire – May 12, 2026

  • Ocumetics Announces Offering of Units

    Calgary, Alberta – TheNewswire – April 29, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a private placement (the “Offering”) of up to 2,800,000 units of the Corporation (“Units”) at a price of $0.55 per Unit for gross proceeds of up to